Display options
Cite
Grant TJ, Mehta AK, Gupta A, et al. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget. 2017;8(45):78556-78572doi: 10.18632/oncotarget.20833.
Grant, T. J., Mehta, A. K., Gupta, A., Sharif, A. A. D., Arora, K. S., Deshpande, V., Ting, D. T., Bardeesy, N., Ganem, N. J., Hergovich, A., & Singh, A. (2017). STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget, 8(45), 78556-78572. https://doi.org/10.18632/oncotarget.20833
Grant, Trevor J, et al. "STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines." Oncotarget vol. 8,45 (2017): 78556-78572. doi: https://doi.org/10.18632/oncotarget.20833
Grant TJ, Mehta AK, Gupta A, Sharif AAD, Arora KS, Deshpande V, Ting DT, Bardeesy N, Ganem NJ, Hergovich A, Singh A. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget. 2017 Sep 11;8(45):78556-78572. doi: 10.18632/oncotarget.20833. eCollection 2017 Oct 03. PMID: 29108249; PMCID: PMC5667982.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Sep 11;8(45):78556-78572. doi: 10.18632/oncotarget.20833. eCollection 2017 Oct 03.

STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines.

Oncotarget

Trevor J Grant, Anita K Mehta, Anamika Gupta, Ahmad A D Sharif, Kshitij S Arora, Vikram Deshpande, David T Ting, Nabeel Bardeesy, Neil J Ganem, Alexander Hergovich, Anurag Singh

Affiliations

  1. Department of Pharmacology and Experimental Therapeutics, Center for Cancer Research, Boston University Graduate School of Medicine, Boston, MA, USA.
  2. University College London, Cancer Institute, London, United Kingdom.
  3. Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA, USA.

PMID: 29108249 PMCID: PMC5667982 DOI: 10.18632/oncotarget.20833

Abstract

Pancreatic ductal adenocarcinomas (PDACs) are highly aggressive malignancies, associated with poor clinical prognosis and limited therapeutic options. Oncogenic

Keywords: Hippo pathway; KRAS; kinase; oncogene dependency; pancreatic cancer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they do not have any conflicts of interest.

References

  1. Cancer Res. 2004 May 1;64(9):3052-9 - PubMed
  2. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 - PubMed
  3. Oncogene. 2003 Mar 27;22(12):1880-91 - PubMed
  4. Lung Cancer. 2007 May;56(2):175-84 - PubMed
  5. Genes Dev. 2015 Jun 15;29(12):1271-84 - PubMed
  6. Nat Rev Drug Discov. 2014 Nov;13(11):828-51 - PubMed
  7. Nat Med. 2015 Oct;21(10):1163-71 - PubMed
  8. Mol Cell Biol. 2008 Apr;28(7):2426-36 - PubMed
  9. Genes Dev. 2010 Nov 1;24(21):2420-9 - PubMed
  10. Int J Cancer. 2013 Sep 1;133(5):1259-65 - PubMed
  11. Cell. 2012 Feb 17;148(4):639-50 - PubMed
  12. Nature. 2010 Apr 15;464(7291):993-8 - PubMed
  13. Cancer Cell. 2009 Jun 2;15(6):489-500 - PubMed
  14. Virchows Arch. 2001 Dec;439(6):798-802 - PubMed
  15. Genes Dev. 2016 Jan 1;30(1):1-17 - PubMed
  16. Oncotarget. 2016 Jul 12;7(28):44142-44160 - PubMed
  17. PLoS One. 2015 Aug 25;10(8):e0136566 - PubMed
  18. Genome Res. 2002 Jun;12(6):996-1006 - PubMed
  19. Genome Biol. 2006;7(10):R100 - PubMed
  20. Nat Med. 2011 Apr;17 (4):500-3 - PubMed
  21. Curr Biol. 2008 Dec 9;18(23):1889-95 - PubMed
  22. Mol Cell Biol. 2011 Apr;31(7):1382-95 - PubMed
  23. Cancer Cell. 2016 Jan 11;29(1):75-89 - PubMed
  24. Cancer Res. 2017 Jan 1;77(1):153-163 - PubMed
  25. J Biol Chem. 2017 Mar 10;292(10 ):4089-4098 - PubMed
  26. J Biol Chem. 2014 May 9;289(19):13461-74 - PubMed
  27. Sci Signal. 2014 May 06;7(324):ra42 - PubMed
  28. Genes Dev. 2008 Jul 15;22(14):1962-71 - PubMed
  29. Cell Signal. 2014 Aug;26(8):1657-67 - PubMed
  30. Cell Death Differ. 2004 Jan;11(1):99-109 - PubMed
  31. Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1281-90 - PubMed
  32. Nat Methods. 2007 Apr;4(4):359-65 - PubMed
  33. Sci Signal. 2013 Apr 02;6(269):pl1 - PubMed
  34. J Clin Invest. 2013 Feb;123(2):727-39 - PubMed
  35. Sci Signal. 2010 Jun 15;3(126):ra47 - PubMed
  36. Science. 1996 Apr 12;272(5259):263-7 - PubMed
  37. J Clin Invest. 2012 Feb;122(2):639-53 - PubMed
  38. Curr Biol. 2015 Oct 5;25(19):2479-92 - PubMed
  39. Oncogene. 2005 Mar 3;24(10):1794-801 - PubMed
  40. J Biol Chem. 2013 Sep 13;288(37):26678-87 - PubMed
  41. Science. 2008 Sep 26;321(5897):1801-6 - PubMed
  42. Nat Rev Cancer. 2003 Jan;3(1):11-22 - PubMed
  43. Cancer Cell. 2014 Mar 17;25(3):272-81 - PubMed
  44. J Biol Chem. 2003 May 16;278(20):17609-14 - PubMed
  45. Nature. 2004 Dec 23;432(7020):1036-40 - PubMed
  46. Cell. 2006 Mar 24;124(6):1283-98 - PubMed
  47. Cancer Sci. 2008 May;99(5):986-94 - PubMed
  48. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  49. Cell. 2009 Mar 6;136(5):823-37 - PubMed
  50. Nature. 2012 Mar 28;483(7391):603-7 - PubMed
  51. J Cell Sci. 2013 Oct 1;126(Pt 19):4358-68 - PubMed
  52. Genes Dev. 2010 Jan 1;24(1):72-85 - PubMed
  53. J Biol Chem. 2010 Nov 26;285(48):37159-69 - PubMed
  54. Cell Cycle. 2011 Jun 15;10(12):1897-904 - PubMed
  55. Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080 - PubMed
  56. Oncogene. 2017 Mar 30;36(13):1804-1815 - PubMed
  57. J Biol Chem. 2004 May 28;279(22):23806-12 - PubMed
  58. Curr Biol. 2015 Feb 2;25(3):296-305 - PubMed
  59. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  60. Nature. 2016 Mar 3;531(7592):47-52 - PubMed
  61. J Clin Oncol. 1997 Jun;15(6):2403-13 - PubMed

Publication Types

Grant support